Clinical trials: Post-ischemic Stroke
Ischemic Symptoms, Cerebral Infarction
Pletaal SR Post Marketing Observational Study
This is a Post Marketing Observational Study of cilostazol (Pletaal® SR capsule). As this study is observational in nature to collect the safety data after administrating the Pletaal SR capsule, from baseline to 16 weeks.
- Trial name
- PLTSRPMOS (NCT01782833)
- Testing
- This is Non-interventional study
- Where
- 4 sites in South Korea
- Volunteers
- 3,635 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this…
- Trial name
- PROST-2 (NCT05700591)
- Testing
- rhPro-UK, rt-PA
- Where
- 72 sites in China
- Volunteers
- 1,552 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Ischemic Stroke
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients.
- Trial name
- NCT06135103
- Testing
- talfirastide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Constant Therapeutics LLC
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Stroke, Ischemic
CASTRO1 - Study on CRP Apheresis After Ischemic Stroke
CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke.
- Trial name
- CASTRO1 (NCT04417231)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Pentracor GmbH
Stroke
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
The objective of this study is to assess the safety, tolerability and pharmacokinetic characteristics of BIII 890 after intravenous infusion in acute ischemic stroke patients.
- Trial name
- NCT02251197
- Testing
- BIII 890 CL
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Pharmacodynamics, Pharmacokinetics
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031.
- Conditions
- Pharmacodynamics, Pharmacokinetics, Healthy Volunteers
- Trial name
- NCT07202663
- Testing
- BB-025, BB-031
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Basking Biosciences, Inc.
Stroke, Ischemic
Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients
This observational, prospective cohort, pilot study aims at investigating usability, operational, and economical factors around 'traditional' and 'technology-supported' approaches to promote a healthy life-style in stroke…
- Trial name
- NCT04733339
- Testing
- Secondary Prevention
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Cereneo AG
Intracranial Aneurysm, Brain Arterial Disease
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.
- Conditions
- Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
- Trial name
- EVIDENCE (NCT04927156)
- Testing
- BALT medical devices
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 10,000 people
- Sponsor
- Balt Extrusion
Cerebral Infarction
Efficacy and Safety of Cilostazol for the Indication of CSPS
This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.
- Trial name
- NCT00216749
- Where
- South Korea
- Volunteers
- 650 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Acute Ischaemic Stroke
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for patients with acute ischaemic stroke in 4.5-6 hours…
- Trial name
- PROUD (NCT03578822)
- Testing
- Recombinant human urokinase, Aspirin, rhPro-UK simulation agent
- Where
- 19 sites in China
- Volunteers
- 149 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Cerebrovascular Accident
Rt-PA in the Treatment of Acute Ischemic Stroke
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to…
- Trial name
- NCT00153036
- Where
- 142 sites in Austria, Belgium and 17 more
- Volunteers
- 821 people
- Sponsor
- Boehringer Ingelheim
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Ischemic Stroke
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and Food Effects of DA414 Granules in Chinese healthy subjects with single and multiple doses.
- Trial name
- DA414 (NCT06525168)
- Testing
- DA414 Granules
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Nine Hong Pharmaceutical Factory
Post-ischemic Stroke
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
- Trial name
- MILESTONE℠ (NCT02422940)
- Testing
- dalfampridine-ER 7.5 mg, dalfampridine-ER 10 mg
- Where
- 66 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Acorda Therapeutics
Hypertension, Ischemic Stroke
Fimasartan Blood Pressure Lowering After Acute Stroke
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients.
- Conditions
- Hypertension, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- FABULOUS (NCT03231293)
- Where
- 27 sites in South Korea
- Volunteers
- 1,035 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ischemic Stroke
IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in the anterior circulation, who received Mechanical…
- Trial name
- IMPACT-24Bt (NCT01874093)
- Testing
- The Ischemic Stroke System
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- BrainsGate
Cardiovascular Disease, Myocardial Infarction
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial…
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Trial name
- EVOLVE-MI (NCT05284747)
- Testing
- Evolocumab, Routine Lipid Management
- Where
- 120 sites in United States, Brazil and 1 more
- Volunteers
- 6,019 people
- Sponsor
- Amgen